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Let-7 microRNA (miRNA) family members have been demonstrated to have potential therapeutic value in vitro 
and in vivo as tumor suppressors that act by regulating Ras at a posttranscriptional level. Previous studies on 
these miRNAs have primarily focused on certain cancers in which mutation and abnormal activation of 
k-ras/K-Ras occur, such as lung cancer and pancreatic cancers. However, the antitumor potential of let-7 in the
case of hepatocellular carcinoma (HCC) has remained untested. Moreover, a major hurdle that limits the
clinical use of miRNAs through systemic delivery, including the delivery of let-7 for HCC therapy, is the lack of
an effective carrier for targeting tumors. Recently, we confirmed the antitumor efficacy of
cholesterol-conjugated let-7a mimics (“Chol-let-7a”) in vitro and in vivo and verified-for the first time-that
Chol-let-7a can effectively carry let-7a to orthotopic tumors in the liver and successfully inhibit tumor growth in
a preclinical model when delivered systemically. We also evaluated for the first time the potential damages that
Chol-let-7a could cause to the liver and kidney at histological and ultrastructural levels after long-term systemic
delivery, in which Chol-let-7a mainly reached and remained at these organs. Lastly, we showed that Chol-let-7a
downregulated all 3 human ras/Ras at transcriptional and translational levels and primarily functioned in the
cytoplasm. Overall, our data suggest that the use of cholesterol-conjugated miRNAs is a promising tool for HCC
systemic therapy.
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Abnormal activation of the Ras signaling pathway is a 
crucial factor in carcinogenesis. Activating mutations in Ras 
proteins result in constitutive Ras signaling, which stimulates 
cell proliferation and inhibits apoptosis, and thereby leads to 
tumor development. Thus, blocking the Ras signaling 
pathway is a key strategy used in human cancer therapy [1]. 
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Recently, the let-7 microRNA (miRNA) family was 
demonstrated to hold potential for use in miRNA 
therapeutics based on the ability of these miRNAs to regulate 
Ras at a posttranscriptional level in vitro and in vivo [2]. 
Human cells contain at least 3 ras proto-oncogenes that 
encode closely related but distinct proteins that function 
abnormally in different human tumors [1]. Oncogenic 
mutations in ras are related to approximately 30% of all 
human cancers [1]. However, previous studies have reported 
that ras proto-oncogenes generated through mutations in 
common codons do not contribute to hepatocellular 
carcinogenesis [3-6]. Thus, studies on let-7-mediated blocking 
of Ras signaling have to date focused primarily on cancers in 
which mutations cause abnormal activation of K-Ras, such as 
lung cancer and pancreatic cancers [7-11]. Most studies related 
to this topic have mainly reported the miRNA effects in 
K-Ras- and H-Ras-related cancers, and the antitumor 
potential of let-7 in the case of hepatocellular 
carcinoma(HCC) remains unknown. 
Recent studies conducted by Calvisi and colleagues have 
suggested that wild-type Ras activity in human liver cancer 
can be promoted by a pathway different from that which 
activates mutated ras [12,13], and that activated (GTP-bound) 
pan-Ras, H-Ras, K-Ras, and N-Ras are markedly upregulated 
in human hepatocarcinogenesis and influence cancer 
progression and prognosis of HCC [12, 13]. Moreover, studies 
conducted in Caenorhabditis elegans [14,15] and 
computational screening (Targetscan,Pictar)have predicted 
that the 3′ untranslated regions(UTRs) of human n-ras, k-ras, 
and h-ras mRNA sequences all contain multiple let-7 
complementary sites (LCSs), which are essential for the 
regulation of Ras expression by let-7. These results suggest 
that let-7 miRNAs are potential regulators of all 3 human Ras. 
Another encouraging finding was our confirmation that 
let-7a inhibited the growth and migration of HCC cells in 
vitro by downregulating all 3 human ras mRNAs and Ras 
proteins [16,17]. These results suggest that let-7 can exert 
potential antitumor effects by downregulating all human Ras 
in HCC. 
A major hurdle encountered in the clinical use of 
miRNAs—as in the case of any new drug or molecule used 
for systemic therapy—is the lack of an effective, non-toxic 
vehicle. Although miRNAs can potentially be used in cancer 
therapies [18], the safe and effective delivery of miRNAs into 
solid tumors remains a challenge. The reported studies have 
verified that certain carriers can be used for targeting 
miRNAs to tumors, including through systemic delivery. For 
treating cancer, viral vector-directed methods [19] have been 
used in order to reintroduce and restore tumor-suppressor 
miRNAs that are otherwise lost in cancer. Kota and 
colleagues [20] reported that adeno-associated virus-wrapped 
miR-26 inhibits cancer-cell proliferation in a mouse model of 
HCC. The use of self-complementary vectors might enhance 
tumor-cell transduction and therapeutic miRNA expression. 
Certain chemical modifications such as cholesterol labeling 
[21] and nanoparticle medicine delivery [22] have been used to 
enhance stability and thus avoid deregulation. Trang and 
colleagues [23] successfully delivered, systemically, synthetic 
miR-34a and let-7 mimics targeting lung tissues by using a 
neutral lipid emulsion and caused a reduction in lung tumor 
in mice. Zhang et al. [24] designed a hepatocyte-targeting 
ligand to increase the efficiency of anti-miR-155 targeted 
delivery. These previous methods resulted in the production 
of strong antitumor effects of miRNAs. However, off-target 
uptake and effects were not the major focus of previous 
studies, and, in particular, the uptake and effects after 
long-term therapy remain unknown. 
Recently, we showed that cholesterol-conjugated let-7a 
miRNA mimics (“Chol-let-7a”) exhibited a high transfection 
rate when used with Lipofectamine®2000 and produced 
satisfactory antitumor effects on HCC cells in vitro [16,17]. 
Subsequently, we performed whole-animal imaging and 
verified that Cy5-labeled Chol-let-7a was mostly targeted to 
liver tissue and excreted from the kidney in nude mice [17]. 
This supported our hypothesis that Chol-let-7a might serve 
as a useful carrier for systemic HCC therapy. 
Next, we confirmed that Chol-let-7a exerted antitumor 
effects on HCC growth when delivered by means of local 
injection in a subcutaneous xenograft model [25,26]. 
Subsequently, Chol-let-7a was shown to effectively carry 
let-7a to the target tumors and produce satisfactory antitumor 
effects in an orthotopic xenograft model when administered 
systemically [16]. These results also suggested that 
Chol-let-7a produces stronger inhibitory effects when 
administered systemically than when delivered through local 
injection. Moreover, the results of histopathological and 
ultrapathological studies suggested that Chol-let-7a induced 
only mild off-target effects, which were non-specific reaction 
changes, in the liver and kidney in nude mice (data not 
shown)[27]. Our studies also suggested that autophagy plays a 
key role in tumor inhibition, but not in the off-target effects 
of miRNAs [16]. Furthermore, we confirmed that Chol-let-7a 
downregulated all 3 human Ras at the transcriptional and 
translational levels and mainly functioned in the cytoplasm 
[16,23]. 
In published studies and reviews, the discussion has 
commonly been limited to the mutation- and 
frequency-dependent effects of the expression of a single Ras 
on tissues and tumor type [1,28]. However, the aforementioned 
results supported the hypothesis that let-7a exerts antitumor 
effects in HCC by regulating all 3 human Ras. The antitumor 
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effects of miRNAs attributed previously to the targeting of 
single K-Ras or H-Ras probably reflect cross-effects 
produced by changes in all 3 human Ras. 
Evidence gathered over the past few years has indicated 
that strategies based on the modulation of miRNA activity 
could serve as a novel approach for treating cancer. MiRNAs 
play numerous crucial roles; they can act as both oncogenes 
(“oncomiRs,” such as miR-155 and miR-221) or 
tumorsuppressors (such as miR-122, miR-34, and members 
of the let-7 family) [29,30]. Certain miRNAs have been shown 
to function as potential miRNA therapeutics for liver cancer 
[18,31-33]. The therapeutic strategy applied involves the use of 
antagomirs for oncomiR inhibition or the restoration of 
tumor-suppressor miRNAs. Our results showed that 
Chol-let-7a and negative-control miRNA mimics 
(“Chol-miR-Ctrl”), which are both cholesterol-conjugated, 
modified forms of miRNA mimics, could effectively target 
miRNAs to liver tissues in vivo. Thus, cholesterol 
conjugation might be a useful modification for developing 
carriers for the systemic delivery of these potential miRNA 
therapeutic molecules for HCC treatment, particularly in the 
case of the tumor-suppressor miRNAs that are 
downregulated in HCC tumors. 
Overall, our data suggest that Chol-let-7a is a promising 
therapeutic drug candidate for systemic treatment of HCC. 
The use of cholesterol-conjugated miRNAs might also serve 
as an effective tool for systemic HCC therapy. 
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